-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FVFhrmJAu+mjzg2AcadPFYvrjUTjbB4brL/NDTXDjqzNG3tsOaLM2xyg8udzn5ep
 ryBkAtdZbqxJEGoBkiGWmQ==

<SEC-DOCUMENT>0001193125-10-231001.txt : 20101018
<SEC-HEADER>0001193125-10-231001.hdr.sgml : 20101018
<ACCEPTANCE-DATETIME>20101018163934
ACCESSION NUMBER:		0001193125-10-231001
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101014
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101018
DATE AS OF CHANGE:		20101018

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		101128403

	BUSINESS ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
		BUSINESS PHONE:		7277230333

	MAIL ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG. B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE
COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event
reported): October&nbsp;14, 2010 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>CRYO-CELL International, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-23386</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22-3023093</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34677</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (813)&nbsp;749-2100 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:1px;margin-top:18px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02. Results of
Operations and Financial Condition. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information in this Item is furnished to, but not filed with, the Securities and
Exchange Commission (the &#147;Commission&#148;) solely under Item&nbsp;12 of Form 8-K, &#147;Results of Operations and Financial Condition.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;14, 2010 Cryo-Cell International, Inc. issued a press release that included financial information for the three months ended August&nbsp;31, 2010. A copy of the press release is furnished
as Exhibit 99.1 to this report and is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Exhibits</U> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;Press Release dated October&nbsp;14, 2010 </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-2-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:1px;margin-top:12px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CRYO-CELL INTERNATIONAL, INC.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: October&nbsp;18, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Jill M. Taymans</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jill M. Taymans</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Finance</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-3-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:1px;margin-top:18px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>EXHIBIT INDEX
</U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:35pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>EXHIBIT<BR>NUMBER</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:34pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>EXHIBIT</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated October 14, 2010.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-4-
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g109684ex99_1.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lilian Stern (Investors) Investor Relations </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stern IR </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">212-362-1200 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">lilian@sternir.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wendi Lee (Media Inquiries)
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cryo-Cell International, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">813-749-2100 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">wlee@cryo-cell.com </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CRYO-CELL INTERNATIONAL, INC. REPORTS THIRD QUARTER 2010 RESULTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Company Reports $2.3 Million Net Income for Third Quarter </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Representing a 72% Year over Year Increase in Net Income </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>OLDSMAR, Fla. &#150; October&nbsp;14, 2010 &#150; Cryo-Cell International, Inc. (OTC Bulletin Board Symbol: CCEL)</B> (the &#147;Company&#148;), one of the world&#146;s largest and most established
family cord blood banks, today announced results for the third quarter ended August&nbsp;31, 2010. Consolidated revenue for the third quarter of fiscal 2010 was $4.5 million compared to $4.6 million for the third quarter of fiscal 2009. The revenue
for the third quarter of fiscal 2010 consisted of $4.2 million in processing and storage revenue and $334,000 in licensee income compared to $4.2 million in processing and storage revenue and $351,000 in licensee income in the same period in fiscal
2009. Licensee income for the three months ended August&nbsp;31, 2010 consisted entirely of royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements. Licensee
income for the 2009 period consisted of $279,000 in royalty income earned on the processing and storage of specimens in geographical areas where the Company has license agreements and $75,000 related to an installment payment of a non-refundable
up-front license fee from the licensee of the Company&#146;s C&eacute;lle program in India. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company reported net income
in the third quarter of fiscal 2010 of $2.3 million, or $0.20 per basic common share, compared to net income of $432,000, or $0.04 per basic common share in the third fiscal quarter of fiscal 2009. The increase in net income for the three months
ended August&nbsp;31, 2010 principally resulted from a 12% decrease in cost of sales, which is partially offset by a 1% increase in marketing, general and administrative expenses. The Company&#146;s overall 3% decrease in total revenue was partially
offset by a 7% increase in global affiliate revenue for specimens processed in the Company&#146;s facility in Florida. Also during the third quarter of 2010, the Company reversed approximately $1.8 million of its valuation allowance for income
taxes. The decision to reverse a portion of the allowance is based on the Company&#146;s historical operating performance, which includes profitability in seven of the last eight quarters, steadily improving operations and positive expectations for
future taxable income. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the third quarter 2010, Cryo-Cell announced that S-Evans Biosciences (SEB),
the Company&#146;s exclusive C&eacute;lle</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> menstrual stem
cell technology license partner in China has opened a new state-of-the-art laboratory operation and research&nbsp;&amp; development (R&amp;D) facility located in a Hi-Tech park designated to become an epicenter for stem cell and genomics R&amp;D;
cellular therapies and stem cell cryopreservation services. The new SEB facility which occupies over </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g109684ex99_1.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
25,000 square feet and includes four Good Manufacturing Practice (cGMP) laboratories and administrative offices is designed to process approximately 10,000 menstrual stem cell samples a year at
the height of operational deployment. SEB anticipates that it may build the world&#146;s largest C&eacute;lle menstrual stem cell bank over the next three to five years. The exclusive C&eacute;lle technology license agreement with SEB in China and
Thailand is expected to provide Cryo-Cell with future royalty fees from the processing and annual storage of menstrual stem cells. Currently, SEB is conducting three pre-clinical studies for heart disease, type I diabetes and liver disease utilizing
menstrual stem cells prepared in SEB and recently reported that the preliminary data are encouraging. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
another major development during the third quarter 2010, the Company announced a R&amp;D collaboration agreement with world renowned stem cell researchers at Monash University in Australia. The partnership will allow scientists from the
University&#146;s Centre of Inflammatory Diseases to conduct pre-clinical studies using Cryo-Cell&#146;s proprietary C&eacute;lle</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> menstrual stem cell technology to identify potential future therapies to treat autoimmune diseases such as multiple
sclerosis (MS). Monash researchers believe that the menstrual stem cell may potentially provide a highly prolific, non-invasive and cost-effective alternative cell source in the development of future cellular therapies to treat this debilitating
autoimmune disease. Under terms of the research collaboration agreement, the R&amp;D study is funded entirely by Monash and intellectual property that may result from the C&eacute;lle MS research is expected to be shared equally by both partners.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">In view of recent encouraging developments associated with proprietary C&eacute;lle</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> menstrual cell technology, the Company continues to believe that
Cryo-Cell&#146;s growth moving forward may possibly be generated from one or more of several promising sources. The Company&#146;s future potential growth drivers may possibly include: fees from C&eacute;lle processing and storage services; revenues
from future therapeutic development that may utilize C&eacute;lle technology; product diversification; global expansion and strategic acquisition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very pleased and clearly energized by Cryo-Cell&#146;s performance throughout the third quarter of fiscal 2010 which includes net income of $3.0 million year to date, or $0.26 per basic
common share; and profitability in seven of the last eight quarters,&#148; stated Mercedes A. Walton, Chairman and CEO. &#147;Cryo-Cell&#146;s cord blood banking business remains solid and continues to generate strong recurring revenues. In
addition, the Company has substantial cash reserves and an expansive technology IP portfolio. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Strategically and
operationally, Cryo-Cell is perhaps at one of the strongest positions in our corporate history. We anticipate continued profitability for the foreseeable future. We also expect that Cryo-Cell&#146;s demonstrably strong and sustained performance,
combined with the Company&#146;s vast potential future upside possibly driven by C&eacute;lle technology; product diversification; global expansion and strategic acquisition, may significantly and positively impact short and longer-term shareholder
value,&#148; Walton concluded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August&nbsp;31, 2010, the Company had $9.0 million in cash, cash equivalents, marketable
securities and other investments. The Company had no long-term debt at the end of the quarter. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g109684ex99_1.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Cryo-Cell International, Inc. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based in Oldsmar, Florida, with nearly 215,000 clients worldwide, Cryo-Cell is one of the largest and most established
family cord blood banks. ISO 9001:2008 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. In November 2007, the Company launched
C&eacute;lle</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (pronounced &#147;C-L&#148;), the
world&#146;s first-ever commercial service allowing women to cryopreserve their own menstrual stem cells. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL
(1-800-786-7235) or visit www.cryo-cell.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About C</B>&eacute;<B>lle </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">The C&eacute;lle</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">SM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve
menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit <U>www.celle.com</U>.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Statements wherein the terms &#147;believes&#148;, &#147;intends&#148;, &#147;projects&#148;, &#147;anticipates&#148;, &#147;expects&#148;, and similar expressions as used are intended to reflect
&#147;forward-looking statements&#148; of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such
forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the actual strength of its momentum, actual future shareholder and enterprise value, the success of the
Company&#146;s global expansion initiatives and product diversification, the Company&#146;s future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company&#146;s
future competitive position in stem cell innovation, future success of its core business, the future costs to the Company related to R&amp;D initiatives, the actual return on investment relative to the Safti-Cell acquisition and those risks and
uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current
Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g109684ex99_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g109684ex99_1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-`"T`P$1``(1`0,1`?_$`,(```(#`0$!`0$!````
M``````@)``<*!@0#!0$+`0`!!0$!`0```````````````P0%!@<!`@@0```&
M`0$'`P(#`PD$"P````$"`P0%!@<(`!$2$Q05%B$7"2(802,D,5$E83+$)D9W
MMSB(@5)%&;%"1%2$E-5FEBA8$0`"`0,#`@,$!`<-!P4````!`@,`$00A$@4Q
M!D$B$U$R%`=A<4(C@<$S=!46"/"1H;%2<L)#@\,U18;18N*SE&4VDF-SDU7_
MV@`,`P$``A$#$0`_`-NNIO4OC#2?B><RWE.3,UB(WA9Q$.SX%)NU6!R0_;:[
M!-3"'/?/5">IAW)HI@8YQ``]9/A^(S><Y!.-P%W9#^W0*H]YF/@JCK^]24LT
M<(\Y`)O8>)MUL/'\5);JF2?E4^1A!Q:L52D3I"T]S&].`GAYZ-EDVH+JIIR$
M5,-$T+=,J)BF<B[AFYCV1C$+RR"!MX7F?#[*[2D^%Y$2<IS4;KO5#Z<2>\;=
M2";;=R.'Z]1TI@T63F,Q,CIBL%LH.T@JVXD,MG\V@87VE5M:S-?N'_Q6ZVD&
M_<X/Y*<I>5D$KD'<B\OY6JKL``RH@Y:WHD@B*I@W%4$QQ+OWB!OV"W@[TX;X
MDG+X3CSAZV"(!)]%RP9?K\H^BU=7&S]D>^5?4N?4L&L=#;8-UQK:^XMI>UC8
MBMV6M_7A\>EY@*;KRKA<LX<L3\L7!98KJ;1R_:HHEYCA9I.M&3)6=D4$5BKN
M&,F0SL2_0BN(%V>#MGMWNO$:?L]VQ^3ACN^-*2=Q.OE<DG0G9N'EN-5%[UZ:
M;+@F02[#C'=N-CNZ>7;;0:W+7!)%K$:UH,HMWJ^2J=6K]2I=K.U2W0[*<@I9
MFH15!Y'ODBJI&WD,8$UDA$2*IC]22I3$,`&*(;9G-#-CRM!.K),C$,K"Q!&A
M!%2`((N-175[)UVIL45-BBIL45-BBIL45-BBIL44#6N;79C31'0&<U8D#VO(
MULZAMCO&D:X!*4L*[4Z";V5?*@188RNQ)G*8++B43++*$02`3G$263MKMC.[
MGRVQ\5EC@C6\DC:JE[[;BX)+6-A<:!C>PI&:985NVI/0>VEBUC'GR[:YX[SR
MT9K2T=XWG#FDZC6*ZVF(2P#%.2E4:D<Q];D82T.(URW5*9,\I)JJ*%$1$A0W
M!M:?C>P.W<A8,?%?E,A`P>5V`COTLJ,I1AULP4$>TG6HV*'+R6,DKRH4F?:"
M-FA%K66P>,`W0O<W\VA`KJ)3XQ->].*G9,6_(G?9*S19%'+:(LS^[-&$PNF`
M'1CUW:5L>-$VKA0NY0'+5RD8/VDV:0=W=OY$4F/RW"X8C<``XX]-U!.IW&[`
MCPVE3X7IR<?*$UTE^XV]#<MNN;^.W;:UA:][F]M*\6"ODPU":><S,-,_R1U5
MM!RLLXCVM<S!%LF31B<91UVZ/?2BL2@R@)JI+O"@B$DV106;'*<[HI@$NYSR
M?:'%\IQC<]V4\DN,A/J0-^40`?9!):X`+E6+%E:ZGRE:]ID.C^ED@`^!\#6@
M!%9)PDDN@JFL@NF19%9(Y5$E4E"@=-5-0@B4Z:A#`("`B`@._;-/KZT\KZ;%
M%38HKD<@2#R)HMRE(Y<S9_&U>=?,G!``3(.FD8Y7;K%`P"4135(`^OIZ;%%*
M2^([4CFO4%IZS_;\P7I_=+'4LERD)7I-\W9H*QL6ACBL3*31(K1!%,Y"2;Y5
M7>8!'>?]VU]^8/!<9P&?CP<5&8XI,?>P+,]VWL+W8FV@&@TIKB2O*I+FY!I-
M'_,>UJ>-=Q]];#UGOCXKS>AB=W8.JX.W\OH^#@X?3BW<7\NTS^JW"?I;X7TF
M]#]7_BK;W_+VONO>]O\`<]WZ*3]>3T]U]?5V]/"CLU*MG7R"_*=3=,[M\_4P
MCIW07DKG%)'3;M7\C"BW=VTX@<5A&1D9-9*+*<2F(+5`0Y8"(G%#A9U[7[*F
MYR,+^E\^4Q0MJ'5%T8BX(\INVEB0PUT`J/G9,_,^')`"E@DD?G8%0/4!;85B
M;=Y"I)W`$>]<+HXC(R.A8YA#P[%I%Q46T;Q\;&L&Z31BP8M$B(-6C1J@4B+=
MLW1(4A"%`"E*```;9AJ3<W))N2=22=223J23J2=2=34]7NV**';5;@"NZG,"
M9$P[8&Z!C66!>>/2*B2)W$#:FJ*BT!-L%EB*`T>,WX%W*@`B4AC!N$!$!D>(
MY*;B.3AY/'_*PN#XV(^TI`*W!'@38Z7KQ(@D0H>A%+;TJ$SE\8^A3*\MJ;@F
MMEA,53["RU"!IUB9R:R4#<)2&AI."C5W"#1!H@QL3XST"*!N,9TJ8#"([@M7
M,R8G>_=L:\"AADRE"DS:7D4,2S;3)8;%51;V=/$HPJT$-I#>Q\/I_>\:+BV_
M(II^QEIUQAJ&RI)O*DRRQ76<_5*(V*A-W21!VW.Y,U:,456R!B-2%W*NEE$&
MA#F`HJ`8Q0&OX?;W+<CR3\7@1>MDQL0VT^4`&Q)9K6'\)\`3I4=#SV%/AQ94
M0<O-&SI'8>HP2]_':HTMN9E3<57==@"+M6^7R,MF.\T959Z:,K,:9AJLU*V/
MW4NJTC74_#V6;D8AV^B!<M"1*S2!(S26<'([4-P+EW%W>HRTW9F7'GXW')EX
M$N3E2F-?3E+[&`O]Y9+J#T!L=1:GBY\<D*SP*\D+;;,NTC:WV[E@"H\=I)((
ML#3.<"YFJVH3$-%S'3!5+7[S#$E&S5P=([N.<)K+,Y",>"B8R8.HY^V42/N]
M!$F\/00VK&=A3\=F2X.4-L\3E3^#H1>QLPL1<"X(-J<8\\>3$)HK["3U!4Z$
M@Z,`>H-C:Q&H)!!JWMFM+4#=OUQ5.OZQZ9HR@Z9/VR]6&#2L%AG(UTQ2B*7'
M*,QE#*2Z!S*/E`3B%4'`B0@%X7!/7\=IF/@LV3@Y.X#M7!CF6/S;@S,PZIY2
MI4:@G<+$$>%-Y<CTY%B5&=F(!V[?*/Y3;F&@\;7;46!J@M0/RSXEQM?Y/#6#
MZ#=M3^8(I9TS?US&C1RX@F$FQ610?1KJ=81\W(NE8]5<I7*S".?-6Z@BFHJ5
M0IR%F>-[)Y++Q%Y/D)(<'BVL1),VTLIW'R+U+64D*Q0N+%;@WI',S?AXF>%?
M4D47(\W0$;O=5V)"W("J2S`+I>XIYS\KFHC'HMIO/'QXY=HE`6W.W=IKDQ*6
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MC/%D^,13$H;:+SD@[9[-P^(PMBYG()ZD\B&S,A`8*WVK%751T6R.`#N:\-"T
M^7G@2,BF$EF59+FQ++&"I2Y1P&8GR$.@52ZAC6F+;*ZG*FQ12Z?DOT9#K'P$
MXKM6BH!;+54D6LK09.:.#),R+M=)G8Z^ZE2IJG;1DK&*"J<HD4*9=JD&X-XF
M"S=I=P-VYS*9S&3X,@B54L2RV)6P)`)#V()-P-UCJ06N5CG(10K,K*U]+6;0
MC:UP3MUOI8W"ZVN#>NC:I9>QWIJQ?1<\N&CG)%)KQ*Y.2;>42E49%K$F.C&O
MU)!--!-0PQQ4RF$2$W`3U#:*YC(P\OE<C)XY&CP9)2R*>JJ=;'S-K>_VC2\:
ML$"MJ]J!O+/R]T)GD%]B;2SAZ^:LKY%N#MY%2D%=Q].3.BJ9LX.UGF<+99-R
MR:NDCIF?=N)&'$O$DY4((&VLF+V3F+BKR7/31<=QQUO(;RLNT&Z1+JQ%P"A*
MN/%;4VERGW*F*HD?>`VI`"ZW(-C<CP!L#_*%<&Y^7+*F)I-H?5;H:ROANEN7
M2+52\0DDYMD:T6>K;VB2YI&KUB"`R390HG(64,X5Y9Q31$WY8.H^R\#DUV]M
M\GCY62+_`';JT#M8$@1AKER;'V`=2P&M)?&RC*]!XR(PEV;S:%C9`#MV$&S;
MO/N2RW4A@0T0N5<?YJT^6+)&,+/'6ZFV.AV5S&3$:<_`80AW8+-7;9<B+N/D
M&I_I6;KIIK)&]#%#:CY&-D8<[8V4C1Y"-9E86((\#^ZWLIQBY>/FQ>MC-NCN
M0=""".H92`RD>(8`CV4G#X*?\JVJ+^^"9_PDINVG?-K_`!7%_-/[QZ2P/<;^
M=^(5G\_L9_J2_IFUB_SW_2?]&DOZK^WI\'Q/$+,?(+\A4[+)%6FD91RJDX<E
M,J[;J2N3[F,GREC[S)<T6R93AZ"8`#]P[5[O4#]3."_^(?\`*C_CI3%`&1*!
M8"_XS6B_;*:?U-BBIL44N?Y:2\7QZZCR[]W%!5`N\/PWY(IH;]K=V$;=X8)]
MDC?\IZ1R#MA9O9;^,4#?Q;:3(W.%*HNK'4?!QUQ>0E8A,=Z>:?+D/(URFX_H
MZCINRL@13L#L'4U,/U3J(K&()DB$]=YA`0D>[N1_1>5/VYQ$KC'$S/D/;:\D
MK:[&(ZQQ@V4`V)-^HJO<)P28<'IY/IS(I0QN5VO9&+J'MY3L;W&&I'O:T\&]
M8ZJM_H=MQY-1$>I7KA7).M2C,K1$B)V,DT5;"7EID*&Y$R@'*'X&*`[4..1X
M95FC-I58,#](-Q_#5D*?=F-/+I8:#3333II[.E)2^'>[S.(;QJ1T#W]RZ)8\
M17.8ME'1?G%1=[5@>M(2971$?1%DHV6@Y!),OIQ2JIOV\6VA=]0+R,.'W;B@
M&#,A592%*@3)HQ;Z6LRK_NQ>RU,,$SQLV+,R.L:J`W1RVNXLH\J@^4@+T+,#
MI:GG6.P1%3K\W:+`]1C8.NQ,A-S$BX-PH,8R,:JO'KM8PB&Y-!LB8P_R!MG8
M!8A1J2:DJQ](YLOS#%&L+Y`7(*0^3M3V1!T_826,LF:2J-?>N#R-]DJV].(J
M"$-!.6<*BH0=Z0M3"&VV2<9A'EN*[+8J<7CX7RL@C=9W*AW4#V,+2#V7*U77
M]1H)_3:8,THN6+!]A\Y]!AJ2MPB@>5;%#TK05\:FD.GZ8-.=&<]FB'.4[]7X
MZVWVX$0(O*.UIUN62CH-*16(9T2/AHUTFD9,IN!1SS5?43[]LU[IY^;N'EY<
MPL?@PUHEN=H0:`@>&[WNFFZWA3[C,00HV7*MLR>Q;WM%%]B;7U3:#=DZ"1G(
MZTPYRU;/6ZS1XW0=M7"9DG#9RDFNW72.&XZ2R*I3IJIG#T$#`(#M7*DR`P*L
M`5-((LNC?(>FC71:;GIPDXBL8:S=0))I9L;(*2!BKNK,20BYR.@86/\`R&[V
M"D4ADXI5<I6K<KHS<GH00#&_V@?VO.'^4_$<3\N,/A<ON+YOYPDEXZ)"%QX(
M82@23D)SYTQYG+P!8+S7C#6LU77L;Y;9/<B9/+SY:XG;F/)]_+(=S`ON8B,'
M0!/+;=<!6``THG/BTTX,M)M?R[B5[+J2MBD+5%6-H\E6!(NQNZNW@V<>T:RS
M5,>2J[B9(ZZAS(;T2IOT?^N8VT;\L/VL8OV@NXLKMGNKA6[9^:/$X$3Y6$9?
M4QYT:>=6FX]GM+)#!]S%D^H-T4TJ`^5TNKW3\NYNTL&'F,/*BS^!RI76.>-3
MIMMM61O=W/Y]H%@=CV&E-BVW:J-4V**FQ12B_F<U`6;"NE5K6:9)/8:QYLN#
M3'02\<HHD]8P`,'DY9DT%4OK1&5B(T[(3`(&`KD>'UW;7;L'AH>8YX'*57P\
M=#*ZDVO;1/K&\KN'0K>^E1W),#!\/)&'@E#*Y)`"J5-[@ZD-[NFHO<Z`T36A
M/2'0M(6$*U4X>)C!O\S&LYC)MN%L@$U8;.\2!P[;N'NX7':X85>D9H<7`D@B
M4-V_>.T+W#S^;W%R+9N:WE!(C3[,:>"C^DW5C<FG.+$\4"K+L]?:-VV^TM;7
M;?6U^E];46-RJ%1R%69FF7:$B+/5K"Q<1LS!S#=%['OV3E,R2R*R"H"'J0P[
MC!N,4?4!`?7:&CEDAD6:%BDR,"K*;%2-00?`@TX(!%CTK/'HT&4TDZJM:.A-
M>55?8[G*+;\CXN2=&,HNU,W@'LHW20)QBBS;KUD7)5BD#\Q5JF8?QVT/NF1.
M?[;P.ZRMN1,C8\Y"@!V07WD]=-%7ZS>H?!D;%D^#RV`F=VV$[09;#=N"KH"5
MN2O4!;GK7<_!3_E6U1?WP3/^$E-V?_-K_%<7\T_O'IU@>XW\[\0K/Y_8S_4E
M_3-K%_GO^D_Z-)?U7]O3S\42)-''S-93IEGYL#2-499![6GYMR49)R-L>*6N
MO)I&6./Z-E/N7T>=01(1-R02@`[P#:L9RR\_\N<;,C;?D<9*R2*!;:ALJEB;
M#RQA&TN3N]MZ\QI/CYVW>&A<L3N'FU-U5"NT`*;CS*Q(`N;W)T@;9?4K4V**
MXS(MSB,=4*XWR>D&47$5&MS%@?/Y%8B#)NE&,5G0&<*J'3(4AU$P*&\P;Q,`
M!ZCLK##)DS+CP@F5V"@`$FY-AH+G^"O+L50L`"0#I>U_PZV^NU9FF>HO4OJH
M^,G7UEK.5S&Q4T9K'U;Q?$%JM2KA:\JUR'7INRL17K\)&/I0C:-GX=`AG2K@
MY>281.8YCFVV)>*XS@^^>(XO!B"921%IG$C.'=HG7HQ.VQ1FTM<.-``*C(IW
MR,-WD*^H+!E!#;&T)4D`7M<=0"18V%Z=?\99"DT":4P*&X#8B@%!_:.\ZIW2
MJAO7_>.<1_V[4#O7_P`LS_SAOQ4^QOR"_51T[5>EZS^_(A'/-(FNK3-KH@DS
M(4ZXR['&.7TTE!:,Q(!#1+B0E52EWN3NZE*F=)I&-N,>ND_F_P`X-&[6*<WV
MWR';$H^_C0Y4)VLQ!0`.+`^RRJ`.LC'705$Y$,46;'*D;#<Y9F7RJ6`"#U""
M"Q93H&#`A-;%%HD_E]SLK3])"-!I3@7]NU+3,+CJM,F`D</92N3)"2-D!NTW
M&%9"5@$S,BFW@`*.R[AW[MHGL;$BGY],S+)3"P4.1(W38(]5)%B;;[`@"]J7
MY!I-B0Q>H&D<"ZA2`!YB'W7LK@;+J"UV%BI\P7A\G>GW[;=$6AS'\>W(G"8T
MOB9LAK)HI+,W]LL$>PDYQ^X=[DQ0"2L1GJA0`NY0IN$?0-K1V/RIY7N7D,G)
M4MGY.-,R>9CL`!NB@WNH!55!/E``%1F9`\<F'+/$)'A23=,MU2,E5W>2[$B2
MQ`U8K;J36DC&D@PEL<8_E8LJ)(R3I-4D(XC?=TY6#V"8.694.'>7DE;J%`N[
MTX=VV3['C^[D!$BZ$'J"-"#]-ZGXY$FC6:(WC<`@V(N"+@V-B-/`@'VUVVQ7
MNE9ZUM0]0PKJ&P%673R4;7K)*`1E4&-CD)5LU>'EUV35W.(F<=0SC7"QQ1*J
M1NN`G`0X?01#XO\`VA?V9?FMWCWE!\_?D?-AKW5P>"$R\;(=H_BH@UE]%R'1
MY-I"/`?1&Q1)Z@:M>^7W?_;O"\1D=H=U02OQ.=+<R(;[;A19E&U@NA;>&N.F
MTUR^E?5?6;SK:R[@RX,[#`Y<K%8=LU1L)8J,;2\M$OF*EAAHV-9"XYQFT$$=
M(-%RK!U3158_*+RN,]E^0G[,/S4[*[BS?VAOG1R.)D]V\UC?`XV)A.9,?#Q-
MZ3,TDKQH[333(4]*S+#\.[F65LGR,._/F/V]RG&8G8W:N+-!P>/-(_J3:,\B
M-(BJEY&)5T=ID)!9T.HC].S-TV^JZS"IL44'VO//[S3/I6RIE6$EV,1<(^+;
M0]$5>I,W1E[;./4&+`K%A(%4:2+UBT.X>@BH10@IM3F.0Y"F*,UV[Q;\SS6/
MQZC<CR`MUML7S/<C474%0=-2!<$BF^5)+%`7A4/)I8%MO4@$WLVH%R!;4BVE
M[C-=J^NV?\NZ&]&&=-25SEIV>N&:K\1E)LH.K5I<E1<Q+EU4I5BPK,%`-DI,
M\9%.S)B8@B(!O$1]!#7.!P^-QN[N6P>`B3X>/`";'+,AD#KNN2S$HQ(!U]N@
MJ(Y!I<KB28/1FD=6V![&-[@@![:%2=&M?2]-<;?$9:G;=NZ;Z^M4BS=RBDN@
MLE=I,Z2J*I"G343,$KN,F<A@$!_=M0OUX_[3P_\`T_\`Q5+?"D:%Y`?KK[?\
MH6X?_O;51_\`-)3_`-5V/UX_[3P__3_\5'PW_N2?OUX*'\:E)P-EN5S=(:HK
MGE7*-:QMD:-"`O<O$2MADHV:H,_"'(Z57>+V,6\;'OU%4B[Q3(!1].'?LAR7
M>V9R7$OP:XV'CX;NK$0HR6(8-<#>5\Q`N2NM=3&$;B0EBUO&JR^"G_*MJB_O
M@F?\)*;M8_FU_BN+^:?WCTC@>XW\[\0K/Y_8S_4E_3-K%_GO^D_Z-)?U7]O6
MN'Y)-!Y-86/HJPT-XUK6?\8F[GCFS**"S&21;K&?GJ+Z23$%&#=V]`%FKC<8
MK9U]1@X3'$,R[3[D/;V>?B5,W$3KLFCZ@J?M;3H2OLTN/'04YR,4SLLBNRNE
M[`&RF_\`*TN;=5U%C[:"[3S\N,SAQ5E@/Y!Z)<<=92J2<;#N;[V)V[+.,/U#
M=O8+/!M$3O2'4(@0HOXPKYF_$#.""4HB`3W)]C#/ORO9CIE<.]SL#`/$1J4L
MY!/@54^<`@%>A9FG)A5O/'*$"N2VT@^0VML_*$OYBFU"&"W!\RW/N2^4W0?&
M07D"NH"`<M.)4A6<=#6F1FSF13,H(!`LX-68*!P+N(8R)2&,(``[]JM#VKW)
M/,L"8.2'8V!:-D7\+,`JCZ20*>29F/'&LK$E6*C0$GS$`74`D`7\Q(`47+6`
M-*8U*ZJ\O_*S9&>E#1W2K)&X95E6KK*F3["R7CF;R.:+$62-.'(8S6"K*)/S
MTF+E3N$NJ!4P;E`@CM?.'X3C^QT_6#NAE;ED%\?&1@7OJ`^AU-[C<#L0:EB3
MM#;UY<P&-$9%W,"38W`-@=";!AY@#9K&Q`-Q1QZV,"T[3-\2.5\-4@G'$U&H
MTQ%W**H)MWE@G'.2J:XF[`_(F8^YU*OSG.!1.IR4N!(#"4A1VK_:N?D<KW[C
M<CE$F>:>1C<WL/2>R@V%PJV4:#0:ZTXEBCBQF6,`7L38`7.@N?:=!J==`.@H
MH?C-_P`@NE'^Y^N?]#C:-[V_\LS_`,X;\5*8WY!?JHY]JM2]!SKXT]-=3>E3
M*^,>W%D+`,$O9Z24J'4.TKA6D5G\8G'$#]CZ7;@O'%'_`''I@_'::[=Y:3@^
M:QN31MJQR#=UML.CW`U-E)('\H`^%-\J*2:`QQ,%D-M2N[H02+7'O"ZWOI>^
MMK%!F@22ONN_5-II;94BS^,:$L7%!X*B[DXR]RA)AHA%/I,5`.V[L6S1[$3M
M]YC"U9G#T*)MM)[GQH.T>&S(N.E!?E\@%1H'CQ[%F%SYF62Y5]`%+#6_2,PQ
MF,\<<EGCB9@69V+E?L$V0*9+Z,-%"BX9CI6A36=IKB]66G:_X7?.THR1G&!7
M]6F56Y'1(>V10BZ@WRB)S)@=$'(<M0`,4>6H8=_X#F/!\K)PG+0<I$"QA<$J
M#MW+XJ3KH1^"]KU)Y&-%E($E%]K!EZZ,.AT(O;V&X^BE):(/D#5TGQ#;1SKO
MB+'BNSXT46@J/D"8C)>4A)N`*]4Z..D'C-HY6%@RYVZ.E4BJ1JK`I"'42,D7
MFW+GNVOTW+)W%VJ5R,";SO$GY6%V]X,ER26:[:7))8@;-I+']))C2_"3AC(J
M@L5\Q`9@J747>SG=9@I4!&+,+4Q;)?R>:),:5AY8W&<ZG<5D6RBK&O8_=A<)
M^4<@4.0Q1:PX.$6*CA0P%YKQ1NW3WB90Y2@(A6L3M+N7,G&/%A9"N03=T,:Z
M"^KN%4'V`FY.@UJ1:>%1<L/P&_\`%2W-(&*LJZ^-91_D(S+6)*H8=I2R9,"5
M2<(<%9,D>@="N/(DA]Q5HB+(J9Z[=I@=H^DW"G),($-PVCG<[$[:X`]F<<ZR
M\A(V[+E3W-WC%K?<0`$.BE0HO9]RA")6FE^(?1![H_'5]?)+H0R5<[I6-9&D
M9<T+J,QMTCZ9A(OD-7E\:0G$:/DXX3J-T7UECF!U6;AHJ8.[QIP;E,"J21%6
M7:7<?'XV/+V]W&K2<#D>.I])O:``2`2`;K?:P!VD%B$<O&"N<\%F=%N%MN`V
MAKLB@;M[!BIM<L+*!?KX=/WS/8EE"!0]6-9LFGW+D`F+&RC)5^8>5=Y(M4P*
MJ=-!LS5LE?=.3)F,=L^8I)I&$"D54#UV\\IV'R4$9S^$9.0XEB2KQ$,X%Q8,
MH]YM=1'N`MK8Z41\IC.FXD[@X0@`L5<D"S``E-MQOW`;!JU@":)JY_*_H3IL
M&2:/FQC9%'#0'3*'J<#8YV7<F.43)-56[2*%**<'$-P@].W`@C]8EVB,/M#N
M;.E]&'"G5K7O(IB7_P!4FT7^B]SX"EY<V")E2Y9V#$!02/*+V)'E6_1=Q`)Z
M=#2CK,KGWYJ,VU5M&U*?Q5HQQO+G<J34NF(#*E.L*<L^ZHA@C)N\RS)#H6[9
MDHY3A4%#JJ*[UQ*-[A_1GRYP))#(F1WA,A3:C:0`@-9O8!Y6.X7D8*%&Q2U-
MOO>1C`8/#$R:ZC>I(\"-R[E)(!&Y01?6G$:V]%,#J$TCN<$T*.80LWC^.BY;
M#:`F1:LH^?JC,S>,B%'"HD2:-9V-%6/56,)03*Y%01W`._/^W><EX3FXN5?<
MZ[CZ@'5E>X?2X!;4E;Z!K'PIQ+BDXJXV,RQA2OV0;@$$BPV@%A<;AT)W6/2@
M7T(_)I6,<5AKI;UJKR&&\LX?;,*9'3MR82R+*QPL4@FTC"6)V+-0(&<8,4TR
MF7=F(U?)`59-43&,4+)W%VA-*WZ=[94Y?"9#;E$0):,L3=-@N]E-P=/+T>QT
MICQTD^,S<?D*H@C`]-P;#;T",&);>@TW7(=;-<,64&-F[Y6]&6'ZE*S<=E>"
MR;84&SCLM3Q\X&P.)60(B)T$',NR35A89D)MW,<.5R%*7?P@<VXHP6!V=W+R
M.2,:+#FC)ZM(K1J!<`F[@7(O?:MV(!V@VJ4?(A0;BP/U:T$^@C"66KXZU1?(
M'J`B7=?M6;*A;V.-JC)-GJ!X2IO(U91699,I'A6BVCB/;)-&0E`1<-5%5!W`
M<`&3[NS.+QX,7MKA_3DAP[F68*+R3'0V<&[*`2"/=O8KT-,^.QI((V>8WF=B
MQ-B`2>IVEFVW`&@-M+V%Z_/^"CUTK:HO[X)G_"2F[3GS:_Q7%_-/[QZ4P/<;
M^=^(5G[WAX9^T/\`,E^\/^^;6+_/?])_T:2_JO[>O]!#;"*DZKK(V(<69?AQ
MK^5,=TS(<()RJ]KN-=B[`R!0@E$BA4))LX(50HD`0$-P@(!^[9QBY>5@S+DX
M<CQ9"FX96*D7%C8CZ#:N,JL+,`10QI_&QH63DPE`TQXJ,J'#N:*5QLK%_2.\
M!&+4XF`B/X[T_4-I?]:^Y_\`]#,_^U_]M)^A#_(7]ZBVIM%I>.X-M6:%5*]3
M:\S,J9K"5F(8PL8@9=4RRQDF4>@@@0RJIQ,80+O$1V@WD>5B\A+.?$FYKL,,
M6/$L$"A(44!5`L`!H`!X`"O7::G6+Q`OZO<J_#VFMRI4224%/1[65B7Y&[A)
MV@5VP>)K-G!47*!%"@8H[CD`0]0#;P"1J.M*5]JY6Z_4(.+K%5A8RNUV$:)L
M(>#A63>.BHMDCOY31@Q:II-FK=/>/"0A0*'[MBY.IZT5^R(@`"(B```;Q$?0
M``/VB(_@`;%%#IJAU%4S39@[(&6;%-Q3=2NUU^O7F*SML*TW97"!V]?C&K85
M04=`YE%$^9P`/`B!SCZ%'9[QG'Y'+\A%QN&&:>5POE&XJ"?,Q'L478_0*3F9
MTA9H]OJ[3MW7V[K:7M8VO:]M;=*!CX<L'3./]-\MF.ZQYFF0-2=MDLG20K@`
MO$ZT]<NE*NW7$Y`<(*G;NU53)F'<`&((`&UE[YY&',YKX/#:^!A1+`EK;;J/
MO&2W0.VMO:*B>#CB&*9H5"Q.?*%8F,J+V9$-O3W$DE;;O%B33))[(Y(3*E`Q
MH:*4<&O4'<9E.6*X(1.-\23BU#H*-C%$Z_7!)@!1*(<`D]=^_:FU-4NB#U-X
M!UF5&NQF6=-D/*33K5#=]/;RBY*:5^PN(R'K=MS=5:[F*`?K,3%DZ?=EL'R!
M6AT`340>IN6QQ$[0YCN<3,R\"89&%+)%..C(Q4B_TBD9<>"<J9D5BC;EN`;-
M8BX]ALS"_L)]M52RPAC+'.M"+P+2/CKT^KMY"GR^783*DG<(EVZ:X_KETIU&
MF'R-4E(=ZO&SR3RY$71;I'*F<B!@X@,("$AD=Q<]F0MC9>;DR0-U5I&(/UB]
MJ\OB8L@`DC0A65A<#1E(92/I!`(/@:+>9U89&;ZA<B8+HF-<6GK^+;/CFI/I
MFU9;C*A-R9[M0:O?55H"H#%K*J(1C&R`W2+S`YZJ!MVX-VT-]=.*\>?M;%TP
MODK*M?C<3U:V43"V,JADJZ3#_+=>IUREV]M\Z*C!4BHRS1=>>FT1I?"V1`P#
M).7*;5'<J8!V**\6?[1IJNN4<(4//&F^NW*MY>H1K(.3;K6X%XUQD^D)VJ0-
M-KEP*]9*RL,I;[7;6D8U=$5*DC)J)I*<('XRN\//SN/E];`FDAFL1=&*FQZZ
MCVTC)CP3,KRHK.A)4D`D$@J2/82I(/T&U456,-:#(73[<]4#31KC@CZISV0H
M>'I+QA#RSN=LM,NTS1HB,@U)1%:/9N;3+1Q.00$AY!5_4!X!VD)>Y>XIXV@F
MSLMX7%BIE8@CV$7Z5XEP\2:,Q31HT3=00"#K?4?6+T5$_J.M$%I$C<_X)P]5
M;*QJU.M<S<\;'N<95FE,#%L;86>0*E$S3:-5B9.1J=MJ3R%`R:9&ZJB`JE$$
M]P;0I))N=33GKK790VH/(,7BC$M\REC&+J]CRIDW&M&0J]>N#>R-(B)RA/P\
M-"3RTV5FW1=+,D98%EVY">O`)2F]0';E%#OJ0E*5F>\94JR^BJE:C*_I\3B&
M>2;M>IRI59ZSFI.I1=]6A:`$S#2,A-#!5"PM7:[P%T$!><UB4`53,<'F%R.?
MQTGK<?-+#*1:Z,5-CU&AZ4C)CP2R)+*BM(E]I(N5W`!K>RX`!]M5OXQH+T_W
MG27.U#211%Z1J#A7]TB\Y*5>%<N</$4+C5ICJ<LR<VU>3$1"W2<RFQB!>HJD
M*PDW;1-8.%;C3>Y'<//YD#8V5FY4N._56D8@V-]1?74`_@KT(HE.Y54'ZJ,*
M&U65F>TT95SQ/4Q=I`X^7R;"NJ;US!^[M1Z*Y>1:,/%'Y8,W#VWN42MV;?A-
MQJKD)]6_UAJ4JO&F<<48.T67/4;0L(UFJMX1J9UDC$---7(WMN28RPQV.;[3
M):9AV24/)S--L"*\:X=`F)%NAW%`"B`!TDDZFY^N]%$K]L&G+E\KV+Q1R^X]
MXY?@=;X.Z\?,[CP]OW=;Q^O,_G[_`,=BY]IHJ]=N45-BBIL45-BBIL45-BBO
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M<I4%9^T_RCX^_&?>OW*^[+5?X=VKQSJ>Q>[VICS_`-^/^#^TON;UOBO)_C_4
M</0_D]^V**9#(^`_?W3N;Y5[H_9_DKM_+[;X1X#[T8H[OU?%_%_*O(>AZ?A_
M3=)SN+Z^#8HH9GG=OO!U%^VW)ZSW'PO[B^3^T^[O?LICSMWAGD/]:>W>(='S
MMWU]?SN3].Q17]U&?9W[D:P?=SQ7W9^W/'_3^0>V?GO;NVYI\)]BO(_ZT>?]
M^ZKI.3]/=>@Y'YN_8HJV[Q[#=>R]Z/(/&OL?MOFOF?!VCVJ[YC_R3R;D_P`=
M\XZSI^'I_P`SF<SE_G\O8HH6<*_;=]G^EGSGWM]FO?6P\/O'X[YO[N>=VGL'
MN]XA]/'Y=UF[MWY'.X.?].W1>^G6BKWHOL1]KFN+V]\Q^W[KLX<?:N@[;V[V
M2KON7[(]3^F\>[]W+?UGU>8=WYOT[MN45<F3_`?:?3%WCRKL'NOID\0[?V[N
MG>_):OX7Y!S_`-/VWKN1W'D?F<KCY7KNV**%;,?D7O-J8]@O=KQ?J:E]Y78_
M!>AZSVSJ'*]C?._R//\`VL[?WSC_`(+R./E_Q;G;=THHA;=]LO3X>[WQ^S?V
M?9E[!Q=1X/["[M/7<>Y[_P"M'<.U]D[3T_ZK?S=WZGD[<^JB@IP-]MWV.X'[
MC[[?;U]RL=W/W8\9\T[][BE]M_<CQ#\SQOSKLW3=!^KY73];_P!HVZ.E%=!E
MO[:OLO\`D`]OO<;V-\N2Z[P'L?;_`#7ET+S/VD\B_3=3[F<_R+N?U^0]QXO7
D=L&_C11B?_;7PC_B'F/FO_L;E^,=#_Y;H>M_\5N_DVY17__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
